Analytical Data
-
Gene name
IFN-lambda 1/IL-29
- Application
-
Alternative Names
IFNL1; IFN-λ1; Interferon Lambda 1; Cytokine Zcyto21
-
Species
Rat
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A0G2JWM7
-
Expression Region
Thr25~Ala192
-
Protein Length
Partial
-
Molecular Weight
49kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon lambda 1 (IFN-λ1), also known as interleukin-29 (IL-29), is a member of the type III interferon family, which plays a crucial role in the immune response to viral infections. IFN-λ1 is particularly important in mediating antiviral activity in epithelial cells, making it a key player in the first line of defense against various pathogens, especially in the respiratory and gastrointestinal tracts. The significance of IFN-λ1 has been underscored by its ability to induce an antiviral state through the activation of specific receptors, leading to the upregulation of interferon-stimulated genes (ISGs) that inhibit viral replication. In recent years, research has focused on the therapeutic potential of IFN-λ1 in treating viral infections, such as hepatitis C virus (HCV) and more recently, SARS-CoV-2. Unlike traditional interferons (type I), IFN-λ1 is believed to have a more favorable safety and tolerability profile, as it primarily signals through the IL-28R receptor complex, which is expressed predominantly on epithelial cells. This cell-type specificity may reduce systemic side effects commonly associated with type I interferon treatments. Furthermore, studies have demonstrated that recombinant IFN-λ1 can enhance the immune response, offering a promising avenue for developing antiviral therapies and vaccines. As research progresses, understanding the molecular mechanisms of IFN-λ1 and its interaction with the immune system may provide insights into novel strategies for combating viral infections and modulating immune responses.
